ClearSight Therapeutics, Inc.

Innovation in Sight
Dallas

About ClearSight Therapeutics, Inc.

ClearSight Therapeutics is dedicated to enhancing patient outcomes by developing innovative over-the-counter (OTC) products for individuals suffering from Dry Eye Disease, Contact Lens Rewetting, and Acute Infectious Conjunctivitis (commonly known as “Pink Eye”). We leverage our proprietary dual-action formulation, which combines an artificial tear with a potent antimicrobial biopolymer. Our products will be the first in their class to address biofilm complications associated with Dry Eye and extended contact lens wear. Furthermore, our Pink Eye treatment will be the first OTC medication able to treat viral pink eye, which accounts for approximately 80% of cases.

Tagged with

Team

Problem statement

ClearSight’s proprietary, patent-pending formulation features a powerful antimicrobial biopolymer that effectively targets and eliminates bacterial, fungal, and viral infections associated with pink eye. Unlike antibiotics, this biopolymer acts on the bacterial cell wall, preventing the development of bacterial resistance. Furthermore, ClearSight’s biopolymer can remove biofilm, which is a challenging complication often seen in Dry Eye Disease and infections related to contact lens use.

Traction information

We have completed the development of our formulation, along with pre-clinical testing for anti-bacterial, anti-fungal, and anti-viral activity. We have also initiated our key pre-clinical biofilm study and expect results shortly. In addition, we have partnerships established with our key API supplier, CDMO, and commercial distribution partners.

Milestones

April 2025

Completed key antimicrobial pre-clinical studies

We have finished developing our formulation and conducted pre-clinical tests for antibacterial, antifungal, and antiviral activity. We have also started our key pre-clinical biofilm study and expect to see results soon.

March 2025

Established a partnership with a Contract Development and Manufacturing Organization - Unither Pharmaceuticals.

Established a partnership with Unither Pharma, Rochester, NY, for the development and manufacturing of our clinical and commercial products.

March 2025

Established API partner - Chitolytic

Established a partnership with Chitolytic to supply ClearSight with GMP-quality active pharmaceutical ingredient (API) which is a critical component of our novel ophthalmic solutions.

Updates

Profile created.
Added about 8 hours ago

Funding

Not raising capital right now

$100,000
committed
$3,000,000
round goal
Total raised to date:$240,000

Pitch deck

Pitch is a Capital Factory product. © Capital Factory 2024. Privacy policy.